Adage Capital Partners Gp, L.L.C. Rocket Pharmaceuticals, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$20.66 - $26.72 $1.45 Million - $1.87 Million	70,000 Added 53.85%	200,000 $4.31 Million
Q1 2024 May 15, 2024	SELL	$26.16 - $30.74 $261,600 - $307,400	-10,000 Reduced 7.14%	130,000 $3.5 Million
Q4 2023 Feb 14, 2024	BUY	$16.78 - $31.94 $2.35 Million - $4.47 Million	140,000 New	140,000 $4.2 Million
Q3 2019 Nov 14, 2019	SELL	$10.85 - $14.78 $23.4 Million - $31.9 Million	-2,157,739 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$15.0 - $19.81 $3.63 Million - $4.8 Million	-242,261 Reduced 10.09%	2,157,739 $32.4 Million
Q1 2019 May 15, 2019	BUY	$13.45 - $19.01 $4.59 Million - $6.49 Million	341,201 Added 16.57%	2,400,000 $42.1 Million
Q4 2018 Feb 14, 2019	BUY	$11.21 - $23.53 $8.51 Million - $17.9 Million	758,799 Added 58.37%	2,058,799 $30.5 Million
Q3 2018 Nov 14, 2018	BUY	$18.5 - $25.49 $1.85 Million - $2.55 Million	100,000 Added 8.33%	1,300,000 $32 Million
Q2 2018 Aug 14, 2018	BUY	$14.58 - $23.0 $2.92 Million - $4.6 Million	200,000 Added 20.0%	1,200,000 $23.6 Million
Q1 2018 May 15, 2018	BUY	$11.68 - $19.19 $11.7 Million - $19.2 Million	1,000,000 New	1,000,000 $18.8 Million

243

94.3M

262K

159K

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $638M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.